---
title: "MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296862063.md"
description: "Strong cash position of CHF 68 million funds operations into late 2027, with operating loss and net result improving year-over-year. Multiple DARPin-based oncology candidates advance in clinical development, including MP0712 and MP0317, with key data readouts expected in 2026 and 2027.Original document: Molecular Partners AG [MOLN] Slides Release — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-25T05:12:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296862063.md)
  - [en](https://longbridge.com/en/news/296862063.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296862063.md)
generator: "portal-rs"
---

# MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026

Strong cash position of CHF 68 million funds operations into late 2027, with operating loss and net result improving year-over-year. Multiple DARPin-based oncology candidates advance in clinical development, including MP0712 and MP0317, with key data readouts expected in 2026 and 2027.

Original document: Molecular Partners AG \[MOLN\] Slides Release — Aug. 25 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MOLN.US](https://longbridge.com/en/quote/MOLN.US.md)

## Related News & Research

- [MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027](https://longbridge.com/en/news/296873375.md)
- [Molecular Partners GAAP EPS of -CHF0.70](https://longbridge.com/en/news/296910213.md)
- [After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)](https://longbridge.com/en/news/296918567.md)
- [HAMLET.B: Significant clinical progress and pipeline expansion in oncology and anti-infectives](https://longbridge.com/en/news/297317935.md)
- [Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating](https://longbridge.com/en/news/296952976.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**